In 2021, the Bio-Manguinhos Institute produced 153 million doses of another COVID-19 vaccine (the recombinant vaccine) through a partnership with the biopharmaceutical company AstraZeneca
Building on solid experience
From the Technological Vaccine Complex in Rio de Janeiro, one of the largest production centers in Latin America, the Bio-Manguinhos Institute guarantees self-sufficiency in essential vaccines for the routine immunization schedule of the Brazilian Ministry of Health. It also exports vaccine doses to over 70 countries against diseases such as yellow fever and meningitis, through PAHO’s Revolving Fund and UN distribution mechanisms.
In 2021, the Institute provided more than 233 million doses of vaccines, including 153 million doses of the COVID-19 recombinant vaccine through a partnership with the biopharmaceutical company AstraZeneca.
“The development of a Fiocruz mRNA vaccine is a fundamental step for the advancement in the development of immunobiologicals. With this project and the support of WHO, we are reaffirming our commitment to science and technology at the service of the population”, said the president of Fiocruz, Nisia Trindade Lima.
“We intend to enter the first phase of scale-up and production next year to conduct the necessary clinical studies,” Luiz Lima, Deputy Director of Production at Bio-Manguinhos-Fiocruz added.
From the outskirts of Buenos Aires, Sinergium Biotech studies how to construct a model of the vaccine in a pilot scale, while learning from Afrigen’s experience and sharing lessons learned with the Bio-Manguinhos Institute.
The company was founded during another health emergency, the influenza A(H1N1) pandemic, and for the past two years supplied influenza vaccines to PAHO’s Revolving Fund.
“Having this installed capacity here allows us to pursue challenging projects to bring other health technologies and products to the region,” Fernando Lobos, Business Development Director, Sinergium Biotech said.
For Lobos, the PAHO platform provides a unique opportunity for cooperation for the sake of science and public health. “The truth is that it is rare to see a team so united in pursuit of an objective that we know will bring benefits in a long term”, he said.
“This is not a project. This is a program. It’s the start of a long road that will bring us many options and many vaccines for the region. This technology, undoubtedly, will have a strong impact on the health situation in the Americas and improve everyone’s access to vaccines”.